重度抑郁症的代谢组学生物标志物研究进展

Research progress on metabonomics biomarkers of major depressive disorder

重度抑郁症(MDD)是世界范围内主要的精神疾病,对社会造成了巨大的经济和情感压力。生物标志物的发现不仅有助于改进抑郁症的诊断和加速新药研发,而且可以用来预测抑郁症发生的可能性,推进MDD个性化治疗的进程。近年来,代谢组学技术的快速发展以及它在疾病诊断方面的广泛应用,为进一步筛选MDD相关生物标志物提供了可能。本文将基于血液、尿液、脑脊液代谢组学总结和讨论MDD代谢组学生物标志物的研究进展,目的是使研究人员能够在已有研究基础上作出新的发现,并期望MDD生物标志物早日在临床中发挥重要作用,以改善MDD患者的生活质量。

Major depressive disorder(MDD) is a major mental disorder worldwide, it causes enormous economic and emotional stress on society. The discovery of biomarkers can not only improve the diagnosis of depression and accelerate the development of new drugs, but also be used to predict the likelihood of depression and advance the process of personalized treatment of MDD. In recent years, the rapid development of metabolomics and its extensive application in disease diagnosis have provided the possibility for further screening of MDD related biomarkers. This paper will summarize and discuss the research progress of metabonomics biomarkers in the MDD based on the metabolomics of blood,urine and cerebrospinal fluid, with the purpose of enabling researchers to make new discoveries on the basis of existing studies, and expect the biomarker of MDD to play an important role in clinical practice as soon as possible to improve the quality of life of MDD patients.